Alliance Pharma PLC Posting of Annual Report & Accounts (9068U)

TIDMAPH

RNS Number : 9068U

Alliance Pharma PLC

09 April 2021

 
                                           9 April 2021 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Posting of Annual Report & Accounts

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Annual Report and Accounts for the year ended 31 December 2020 have now been posted to those shareholders who have opted out of receiving electronic communications from the Group.

Printed copies are available by contacting Buchanan by email at [e-mail] or by telephoning Buchanan on 020 7466 5000.

In addition, and as announced on 29 March 2021, the Annual Report and Accounts for the year ended 31 December

2020 are also   available on the Group's website, www.alliancepharmaceuticals.com 

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Oliver Steele 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                  + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSBVLLBFZLLBBF

(END) Dow Jones Newswires

April 09, 2021 02:00 ET (06:00 GMT)